

Dr. David Baram co-founded Emendo and has served as its President & CEO since that time. David guides the strategy and direction of all aspects of the company, including all stages of research & development, from concept to drug development. Under his leadership, David has taken Emendo from the pre-seed stage through a successful acquisition in 2020 and into the present expansion of Emendo with its broad platform technologies, multiple programs, many high-level collaborations and one hundred employees with operations in the United States and Israel. Prior to Emendo, David co-founded multiple biotech companies and a seed-stage incubator in which he was responsible for technological innovation, entrepreneurship and financing. David has vast business experience, conducting the negotiation and execution of a broad range of deals including mergers & acquisitions, out-licensing, and in-licensing, fundraising over \$400 million in private and public rounds, and serving as a member of the board of directors for several biotech companies. David is an inventor of over thirty patents. He completed his Ph.D. studies at the Weizmann Institute of Science under Nobel Laureate Dr. Ada Yonath.